IceCure Medical (NASDAQ:ICCM) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM - Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $3.00 target price on the stock.

Separately, Alliance Global Partners lifted their price target on IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a research report on Wednesday, March 20th.

IceCure Medical Stock Down 3.7 %

ICCM stock traded down $0.05 during trading on Tuesday, hitting $1.30. 858,475 shares of the company's stock were exchanged, compared to its average volume of 676,701. The business has a 50-day moving average price of $1.28 and a two-hundred day moving average price of $1.11. The stock has a market capitalization of $59.31 million, a price-to-earnings ratio of -3.94 and a beta of 0.73. IceCure Medical has a 52-week low of $0.52 and a 52-week high of $1.57. The company has a current ratio of 3.66, a quick ratio of 3.08 and a debt-to-equity ratio of 0.03.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its quarterly earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $1.26 million for the quarter. IceCure Medical had a negative return on equity of 86.96% and a negative net margin of 453.76%. During the same period last year, the firm earned ($0.11) EPS. As a group, equities research analysts expect that IceCure Medical will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in shares of IceCure Medical by 57.2% in the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company's stock valued at $86,000 after purchasing an additional 20,159 shares during the period. Boothbay Fund Management LLC increased its holdings in shares of IceCure Medical by 100.0% in the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company's stock valued at $62,000 after purchasing an additional 20,000 shares during the period. UBS Group AG grew its holdings in IceCure Medical by 1,302.3% during the fourth quarter. UBS Group AG now owns 28,986 shares of the company's stock worth $45,000 after acquiring an additional 26,919 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in IceCure Medical during the second quarter worth $78,000. Institutional investors and hedge funds own 0.62% of the company's stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.